GlassScriptPhysician profile
Salomon Salama
NPI 1104810613
$2,313.97
in general payments reported to CMS, 2019-2025
16 companies · $630 in 2025
The $630 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2021: $182 · 2022: $149 · 2023: $495 · 2024: $686 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,811.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $416.70 | 2019-2025 | Clareon, Eysuvis |
| Abbvie INC. | $328.39 | 2023-2025 | Xen Glaucoma Treatment System |
| Johnson & Johnson Surgical Vision, INC. | $327.95 | 2019-2024 | Tecnis Iol, Tecnis Iol |
| New World Medical,INC. | $244.79 | 2023-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Rayner Intraocular Lenses Limited | $215.84 | 2023-2024 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Horizon Therapeutics Plc | $147.92 | 2022-2023 | Tepezza |
| Allergan, INC. | $131.02 | 2021 | |
| Mallinckrodt Hospital Products INC. | $124.46 | 2025 | Acthar |
| Ani Pharmaceuticals, INC. | $121.60 | 2024 | Purified Cortrophin Gel |
| Apellis Pharmaceuticals, INC. | $117.73 | 2025 | Syfovre |
| Dompe US, INC. | $30.64 | 2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $27.61 | 2025 | Xdemvy |
| Biotissue Holdings INC. | $24.81 | 2023 | |
| Oyster Point Pharma, INC. | $21.50 | 2022 | |
| Amgen INC. | $16.85 | 2025 | Tepezza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $16.16 | 2024 | Miebo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salomon Salama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.